A Double‐Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects

The purpose of this study was to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of BOS161721, a humanized immunoglobulin G1 triple mutation (M252Y/S254T/T256E) monoclonal antibody that inhibits interleukin‐21 (IL‐21) bioactivity. This randomized, single‐cente...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussaini, Azra, Mukherjee, Rajat, Berdieva, Dina M., Glogowski, Christen, Mountfield, Richard, Ho, Peter T.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070801/
https://www.ncbi.nlm.nih.gov/pubmed/31664766
http://dx.doi.org/10.1111/cts.12715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070801/
https://www.ncbi.nlm.nih.gov/pubmed/31664766
http://dx.doi.org/10.1111/cts.12715

Ejemplares similares